Back to Posts

Back to Posts

May 19, 2022 Agency Alerts

EMA Regulatory and procedural guideline: Public consultation concerning the physical attendance and the location of personal residency of the qualified person


The COVID-19 pandemic required manufacturers and importers of medicinal products and regulatory authorities to operate under business continuity mode, impacting the standard way of working. As a result it was necessary to publish guidance on regulatory expectations and flexibility during the COVID-19 pandemic to minimise risks of shortages while ensuring that the high standards of quality, safety and efficacy of medicines made available to patients in the EU were maintained. This guidance has been developed in cooperation between the European Commission, the Coordination group for Mutual recognition and Decentralised procedures – human (“CMDh”), the Inspectors Working Group, the Coordination group for Mutual recognition and Decentralised procedures – veterinary (“CMDv”) and EMA.

Download EMA Regulatory and procedural guideline

Interested in learning more? Contact us today to find out how we can help not only with your EMA/FDA submissions, but all of your global regulatory needs.



ビジネスには複雑な課題があります。ProPharma Groupは優れたソリューションを提供しています。

弊社は製薬企業様、バイオテクノロジー企業様、医療機器メーカー様とともに複雑な課題にチャレンジいたします。弊社の経験豊かな専門スタッフが製品ライフサイクルの全段階で薬事と開発が成功するようにお客様をサポートいたします。詳細はお問い合わせください。

業界で優位性を確保したいとお考えですか? 弊社が最新の競争力を維持するお手伝いをいたします。


すべてのフィールドが必要です。
送信で問題が発生しました。以下にエラーがハイライトされました。